iCAD releases new CAD version
Computer-aided detection pioneer iCAD has upgraded its mammography CAD technology. The new product, Version 7.2, is now shipping with the company’s workstations SecondLook 300 and 700.
Computer-aided detection pioneer iCAD has upgraded its mammography CAD technology. The new product, Version 7.2, is now shipping with the company's workstations SecondLook 300 and 700.
"It is the latest algorithm that works across our product line," said Jeff Barnes, iCAD senior vice president of sales. "It is the only thing we are shipping now."
A variation of this version is designed for use on FujiFilm Medical USA's CR mammography product, Barnes noted. This particular software, optimized for CR, is still pending FDA approval, however.
CAD v7.2, like preceding versions, automatically identifies and marks areas of a digital mammogram. This latest software, however, has improved sensitivity to subtle cancers with fewer false positives and more understandable indications, according to Dr. Rachel Brem, an early evaluator of the software and director of breast imaging and intervention at the George Washington University Medical Center in Washington, DC.
The company claims CAD v7.2 reduces the number of false markings in SecondLook output. Brem reports that tests at GWU Medical Center showed a significant improvement in mass detection.
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
Contrast-Enhanced Mammography and High-Concentration ICM Dosing: What a New Study Reveals
June 16th 2025New research showed a 96 to 97 percent sensitivity for contrast-enhanced mammography (CEM) with an increased iodine delivery rate facilitating robust contrast enhancement for women with aggressive breast cancer.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.
